[Skip to Content]
[Skip to Content Landing]
Views 2,108
Citations 0
Editorial
July 5, 2016

Lynch Syndrome TestingA Missed Opportunity in the Era of Precision Medicine

Author Affiliations
  • 1Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston Salem, North Carolina
  • 2Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Winston Salem, North Carolina
  • 4Associate Editor, JAMA
  • 3Department of Pathology, Wake Forest Baptist Medical Center, Winston Salem, North Carolina
JAMA. 2016;316(1):38-39. doi:10.1001/jama.2016.8291

Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer, is an autosomal-dominant inherited cancer susceptibility syndrome that affects approximately 1 in 35 patients diagnosed with colorectal or endometrial cancers, making it the most common inherited cancer syndrome.1 Lifetime risk of colorectal cancer for men and women with Lynch syndrome is 10% to 80%, and women with Lynch syndrome have a 15% to 60% lifetime risk of developing endometrial cancer.

First Page Preview View Large
First page PDF preview
First page PDF preview
×